Page last updated: 2024-12-04

5,8,11,14-eicosatetraynoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1780
CHEMBL ID458328
CHEBI ID94483
SCHEMBL ID68751
MeSH IDM0023258

Synonyms (74)

Synonym
CBIOL_001864
gtpl2669
eicosatetranoic acid
LMFA01030691
BIO1_000639
BIO2_000169
BIO1_001128
BIO1_000150
BIO2_000649
eicosatetraynoic acid
BSPBIO_001449
HSCI1_000035
IDI1_033919
SPECTRUM5_001952
5,8,11,14-eicosatetraynoic acid, >=97%
MLS-0002886.0001 ,
NCGC00021784-03
NCGC00021784-04
NCGC00021784-05
5,8,11,14-eicosatetraynoic acid
MLS000069514 ,
etya
smr000058640
KBIOGR_000169
KBIO3_000337
KBIO2_002737
KBIO2_005305
KBIO2_000169
KBIOSS_000169
KBIO3_000338
NCGC00018135-01
ro 31428
ro 3-1428
1191-85-1
icosa-5,8,11,14-tetraynoic acid
HMS1989I11
BML2-F04
HMS1361I11
HMS1791I11
SR-01000000036-3
CHEMBL458328
NCGC00018135-05
NCGC00018135-06
NCGC00018135-03
NCGC00018135-04
NCGC00018135-02
5fej8j06dr ,
unii-5fej8j06dr
CCG-207933
SCHEMBL68751
MGLDCXPLYOWQRP-UHFFFAOYSA-N
5,8,11,14-icosatetraynoic acid #
icosa‐5,8,11,14‐tetraynoic acid (d3)
bdbm31752
eicosa-5,8,11,14-tetraynoic acid
cid_1780
HMS3402I11
HMS3649D21
OPERA_ID_402
mfcd00036967
DTXSID20152318
J-004079
CHEBI:94483
HY-124108
etya - cas 1191-85-1
Q27077167
sr-01000000036
SR-01000000036-4
'5,8,11,14-eicosatetraynoic acid'
CS-0084220
ity ,
MS-24251
BAA19185
AKOS040733080

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" 7,12-Dimethylbenz(a)anthracene (DMBA) and 7-hydroxymethyl-12-methylbenz(a)anthracene (7-OHM-12-MBA), but not benzo(a)pyrene (BP), selectively produce necrosis in the two inner zones of the rat adrenal cortex and are toxic to cultured rat adrenocortical cells."( Influence of effectors of prostaglandin metabolism on the toxicity induced by 7-hydroxymethyl-12-methylbenz(a)anthracene in cultured rat adrenal cells.
Hallberg, E; Rydström, J, 1990
)
0.28
" Trilinolenin (18:3; omega-3) was toxic only after prolonged incubation."( Toxicity of polyunsaturated fatty acid esters for human monocyte-macrophages: the anomalous behaviour of cholesteryl linolenate.
Carpenter, KL; Hardwick, SJ; Hird, R; Law, NS; Marchant, CE; Mitchinson, MJ; Van Der Veen, C, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" PGF-A enhanced both mucous glycoprotein release and the 5- and 15-lipoxygenation of arachidonic acid as well as the formation of leukotriene B4 (LTB4) with similar dose-response relationships."( Prostaglandin-generating factor of anaphylaxis induces mucous glycoprotein release and the formation of lipoxygenase products of arachidonate from human airways.
Goetzl, EJ; Kaliner, M; Marom, Z; Shelhamer, JH; Steel, L, 1984
)
0.27
" Cumulative dose-response effects of ovalbumin were obtained on paired parenchymal strips, one used as control and the other drug treated."( Pharmacological alteration of antigen-induced contraction of lung parenchymal strips isolated from the actively sensitized guinea pig.
Buckner, CK; Busse, WW; Songsiridej, V, 1983
)
0.27
" ETYA also inhibits cutaneous immediate-type reactivity to ascaris antigen in a dose-response relationship."( Inhibition of immunoglobulin E-mediated, antigen-induced monkey asthma and skin reactions by 5, 8, 11, 14-eicosatetraynoic acid.
Harris, KE; Patterson, R, 1981
)
0.26
" Maximum contraction occurred simultaneously with the maximum amount of histamine appearing in the superfusate, but the dose-response curves of ovalbumin were different for the two responses."( Studies on the relationship between contraction and mediator release produced by ovalbumin in superfused trachea isolated from the actively sensitized guinea pig.
Buckner, CK; Fishleder, RI, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency15.08950.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency30.02130.004023.8416100.0000AID485290
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency15.84890.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency14.65290.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency25.11895.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency26.65140.002014.677939.8107AID1476; AID1478
LuciferasePhotinus pyralis (common eastern firefly)Potency30.13130.007215.758889.3584AID588342
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency24.06820.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency19.95260.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency3.98110.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency12.58930.540617.639296.1227AID2528
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency3.16231.000012.232631.6228AID1452
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
DNA polymerase betaHomo sapiens (human)Potency1.12200.022421.010289.1251AID485314
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency28.18380.65619.452025.1189AID463254
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency10.00000.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency2.23870.251215.843239.8107AID504327
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency10.69100.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mcl-1Homo sapiens (human)IC50 (µMol)1.78000.40007.134454.0000AID1418
Myeloid cell leukemia sequence 1 (BCL2-related)Homo sapiens (human)IC50 (µMol)0.44150.44153.75295.4780AID2217
envelope glycoproteinHuman immunodeficiency virus 1IC50 (µMol)11.90002.200014.820082.2000AID1986
eukaryotic translation initiation factor 4 gamma 1 isoform 4Homo sapiens (human)IC50 (µMol)32.13001.150012.620025.6529AID855
eukaryotic translation initiation factor 4E isoform 1Mus musculus (house mouse)IC50 (µMol)32.13001.150012.620025.6529AID855
VifHuman immunodeficiency virus 1IC50 (µMol)0.86000.270034.0015100.0000AID1117319
TatHuman immunodeficiency virus 1IC50 (µMol)2.37900.996039.8009100.0000AID1117361
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)0.86000.270026.3638100.0000AID1117319
dual specificity protein phosphatase 6Rattus norvegicus (Norway rat)IC50 (µMol)21.68300.832024.119048.2000AID1052; AID1054; AID1055; AID425
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)IC50 (µMol)17.70000.100012.726563.0000AID1059; AID1077
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)1.78000.00052.773925.1700AID1418
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)1.78000.00052.891925.1700AID1418
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)1.78000.00052.747825.1700AID1418
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)1.78000.00052.780225.1700AID1418
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)1.78000.00053.314249.5000AID1418
Caspase-1Homo sapiens (human)IC50 (µMol)10.00000.00201.70138.8000AID1801388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POsterior SegregationCaenorhabditis elegansAC5010.78003.298012.464924.6150AID493130
Zinc finger protein mex-5Caenorhabditis elegansAC506.71200.300031.0987106.7000AID449745
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID530947Antifungal activity against Trichophyton rubrum ATCC MYA-4438 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530715Antifungal activity against Aspergillus niger ATCC 16404 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530702Antifungal activity against Aspergillus fumigatus ATCC 90906 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531196Cytotoxicity against human SK-MEL cells up to 32 uM by neutral red method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530988Antifungal activity against Candida albicans ATCC 90028 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530956Antifungal activity against Aspergillus fumigatus ATCC 90906 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531200Cytotoxicity against African green monkey Vero cells up to 32 uM by neutral red method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530970Antifungal activity against Fluconazole resistant Candida albicans clinical isolate 1 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531183Antifungal activity against Candida albicans ATCC 32354 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530981Antifungal activity against Candida albicans ATCC 200955 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531198Cytotoxicity against human BT549 cells up to 32 uM by neutral red method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID681133TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID530448Antifungal activity against Candida albicans ATCC 32354 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530957Antifungal activity against Aspergillus fumigatus ATCC 204305 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530959Antifungal activity against Cryptococcus neoformans ATCC 90113 after 72 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530695Antifungal activity against Aspergillus fumigatus ATCC 204305 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID334485Inhibition of soybean 15-LOX at 4 uM1993Journal of natural products, Jul, Volume: 56, Issue:7
Dicranin, an antimicrobial and 15-lipoxygenase inhibitor from the moss Dicranum scoparium.
AID530467Antifungal activity against Fluconazole resistant Candida albicans isolate 1 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530955Antifungal activity against Aspergillus flavus ATCC 204304 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531201Cytotoxicity against pig LLC-PK1 cells up to 32 uM by neutral red method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530718Antifungal activity against Trichophyton mentagrophytes ATCC MYA-4439 at 168.9 uM after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530730Antifungal activity against Trichophyton rubrum ATCC 10218 at 168.9 uM after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530950Antifungal activity against Trichophyton mentagrophytes ATCC 9533 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530941Antifungal activity against Trichophyton rubrum ATCC 10218 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID681123TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID530454Antifungal activity against Candida albicans ATCC 90028 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530961Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531206Antifungal activity against Candida albicans ATCC 60193 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530953Antifungal activity against Trichophyton mentagrophytes ATCC MYA-4439 by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530727Antifungal activity against Trichophyton rubrum ATCC MYA-4438 at 168.9 uM after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530964Antifungal activity against Fluconazole resistant Candida albicans clinical isolate 17 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531205Antifungal activity against Candida albicans ATCC 14053 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530480Antifungal activity against Candida glabrata ATCC 90030 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530960Antifungal activity against Candida tropicalis ATCC 750 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1168381Growth inhibition of Candida albicans SC5314 assessed as reduction in reduction in metabolic activity incubated for 48 hrs by XTT assay2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Polyketide glycosides from Bionectria ochroleuca inhibit Candida albicans biofilm formation.
AID530486Antifungal activity against Candida krusei ATCC 6258 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530708Antifungal activity against Aspergillus flavus ATCC 204304 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530721Antifungal activity against Trichophyton mentagrophytes ATCC 9533 at 168.9 uM after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1168380Inhibition of biofilm formation of Candida albicans SC5314 incubated for 48 hrs by XTT assay2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Polyketide glycosides from Bionectria ochroleuca inhibit Candida albicans biofilm formation.
AID530473Antifungal activity against Fluconazole resistant Candida albicans isolate 17 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530962Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530434Antifungal activity against Candida albicans ATCC 14053 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530441Antifungal activity against Candida albicans ATCC 60193 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530676Antifungal activity against Candida tropicalis ATCC 750 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530689Antifungal activity against Cryptococcus neoformans ATCC 66031 at 168.9 uM after 72 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530683Antifungal activity against Cryptococcus neoformans ATCC 90113 at 168.9 uM after 72 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531199Cytotoxicity against human SKOV3 cells up to 32 uM by neutral red method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID531197Cytotoxicity against human KB cells up to 32 uM by neutral red method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530493Antifungal activity against Candida parapsilosis ATCC 22019 at 168.9 uM after 48 hrs by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID530954Antifungal activity against Aspergillus niger ATCC 16404 after 5 days by CLSI method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Potent in vitro antifungal activities of naturally occurring acetylenic acids.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1801388Inhibition Assay from Article 10.1111/cbdd.12572: \\Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.\\2015Chemical biology & drug design, Nov, Volume: 86, Issue:5
Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (558)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990306 (54.84)18.7374
1990's156 (27.96)18.2507
2000's75 (13.44)29.6817
2010's18 (3.23)24.3611
2020's3 (0.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.93 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (12.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.17%)5.53%
Reviews15 (2.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other557 (97.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]